SCIRENT Clinical Research and Science

As 2024 comes to a close, we’re proud to reflect on a year of great achievements at SCIRENT.    This year has strengthened our commitment to driving innovation in cardiovascular clinical trials, and we’re excited to share some of the highlights of 2024 with you: ✅ We successfully secured and initiated three gene and cell therapy trials. ✅ We expanded our network of leading healthcare providers and partner CROs, ensuring faster patient recruitment and more efficient trial management with a truly global perspective.  ✅ We deepened our team’s expertise by hiring new talent. ✅ Our dedication to cutting-edge clinical research is supported by the guidance of a newly built top-tier Faculty and Advisory Board comprising leading cardiovascular experts.  ✅ Breaking records in 2024: The SCIRENT team boosted coffee consumption by 50% – because staying laser-focused for our clients requires serious caffeine commitment! A big shout out to our incredible team, whose dedication, knowledge, and passion are the foundation of our success. We are equally grateful to our partners and clients for trusting SCIRENT to bring groundbreaking cardiovascular solutions to life. A heartfelt thank you to everyone who has been part of this journey. As we step into 2025, we are excited to build on this momentum – embracing new challenges, forging innovative partnerships, and continuing to make a meaningful difference in patients’ lives. Here’s to a brighter future in cardiovascular health!

After participating in many conferences this year, we can confidently say that CSI Focus D-HF in Frankfurt stands out as a top choice! This remarkable meeting delivers an in-depth exploration of device-based therapies for heart failure. Kudos to Horst Sievert and the course directors for orchestrating such an outstanding and impactful event! #CSI #HeartFailure #Cardiology #Frankfurt

CVCT in Washington, D.C. – Lots to learn and exchange with regulatory bodies, MedTech, Biotech, and pharmaceutical industry representatives, former clinical academic colleagues, current and future customers, partners, and investigators. There even is a wine and cheese poster presentation session. Great to be here! #CVCT24 #ClinicalResearch #RegulatoryAffairs #HealthcareIndustry #CardiovascularResearch

Bio ReFine Ltd. has developed a unique implant-less annuloplasty system, designed for the repair of the mitral and tricuspid heart valves. We are proud to announce that as of this week the first patient in Serbia has received the promising procedure in Dedinje. This innovative technology addresses a significant unmet need, providing treatment to a vast population currently ineligible for care due to the high risks associated with open-heart surgery. #clinicaltrial #cardiovascular #Boaz Shenhav

Back from #TCT2024 in Washington, one of the pivotal events in cardiovascular medicine. It was a fantastic chance for exchange, learning, and networking. Many thanks to the organizers and participants for the inspiring conversations and insightful sessions. The event highlighted the latest in interventional technology and the future of heart health, offering insights that will help our team refine our research and development to improve patient care. We’re excited to apply what we’ve learned to upcoming projects and build on the new connections. 

We are thrilled by the experiences so far at the XXV National Congress of Serbian Cardiologists at the Sava Center, Belgrade! 🌟 Here’s a glimpse of some inspiring moments featuring our fantastic team members Elvis Tahirovic (PHD, MBA, MPH), Jovan Veskovic (MPH, Dipl. Ecc), Milica Lazic, Ema Jesic, Branka Đorđević, Nenad Milošević, Dušan Despotović and Vesna Kocijančić. These engagements are crucial for advancing cardiological research and strengthening our networks.

Meet us at the XXV National Congress of Serbian Cardiologists! 📅 Date: October 24-26, 2024 📍 Location: Sava Center, Belgrade As a specialty cardiovascular CRO established and closely involved in the Serbian clinical research ecosystem since 2012, we are proud to participate in this significant congress that brings together leading cardiologists from Serbia, neighboring countries, and renowned European experts to discuss the latest advancements in cardiology. Come by our booth to learn more about our site network and connect with our investigators. We look forward to inspiring conversations! #Cardiology #Serbia #ClinicalResearch #cardiovascular #savacentar #belgrade #beograd

TCT 2024 in Washington is just around the corner, from October 27th to 30th. We're excited to present our extensive European site network to a global audience, particularly potential US sponsors and partners. This event is a great platform to connect leaders in cardiovascular research. 🔗 Stay tuned for regular updates and exclusive insights from the conference! #TCT2024 #CardiovascularResearch #MedicalInnovation #SCIRENT

TCT 2024 in Washington is just around the corner, from October 27th to 30th. We're excited to present our extensive European site network to a global audience, particularly potential US sponsors and partners. This event is a great platform to connect leaders in cardiovascular research. 🔗 Stay tuned for regular updates and exclusive insights from the conference! #TCT2024 #CardiovascularResearch #MedicalInnovation #SCIRENT

Last day at #ESCCongress #2024 in #London. A very productive event combining a multitude of Sponsor meetings, insightful presentations and exchanges with industry stakeholders and medical professionals. Our Founders Dr. Hans-Dirk Düngen MD, PhD, Elvis Tahirovic (PHD, MBA, MPH) and Jovan Veskovic (MPH, Dipl. Ecc) have been working closely for almost 20 years contributing to academic and industry research. The congress has been a wonderful opportunity to reconnect with study Sponsors and colleagues in clinical operations and medical affairs to exchange knowledge, ideas on how to improve clinical research, advance innovative therapies and ultimately increase the quality of life for Patients with cardiovascular disease.